Connect your AI

Alamar Biosciences ALMR Payments Of Stock Issuance Costs

Payments Of Stock Issuance Costs at other companies

Immunovant, Inc.IMVT

$126K-60.5%

Hinge Health, Inc.HNGE

$0-100%

CG OncologyCGON

$47K-79.7%

NNN REITNNN

$100K+17.6%

Essential Properties Realty TrustEPRT

$152K-35.6%

AeroVironmentAVAV

$1.39M+91.7%

Other financials

Income statement

Revenue$26.0M+98.9%

Gross profit$14.5M+126%

Operating income-$12.3M-44.4%

Net income-$21.3M-178%

EPS (diluted)-$1.74-156%

Balance sheet

Cash & equivalents$64.6M—

Total debt$30.6M—

Total equity-$178.1M—

Total assets$186.5M—

Cash flow

Operating cash flow-$20.3M-55.7%

CapEx$600.0K+8.3%

Free cash flow-$20.9M-53.8%

Valuation

Market cap$1.52B—

Enterprise value$1.49B—

Returns & leverage

Debt / equity-0.2×—

Current ratio5.9×—

Where this comes from

Reported directly by Alamar Biosciences in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfStockIssuanceCosts.

The official record: Alamar Biosciences ’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alamar Biosciences 's payments of stock issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Alamar Biosciences 's payments of stock issuance costs?: Alamar Biosciences (ALMR) reported payments of stock issuance costs of $2.22M in Q1 2026.